Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
APCh | TSXV | CAD | Delayed | |
APCh | CBOE Canada | CAD | Real-time |
For the six months ended 31 January 2022, Advanced Proteome Therapeutics Corporatn revenues was not reported. Net income applicable to common stockholders totaled $1.3M vs. loss of $315K. Net income reflects FV Adjustments of Financial Investments increase from $24K (expense) to $1.7M (income), Share based payments decrease from $73K (expense) to $0K, Foreign exchange gain (loss) increase from $14K (expense) to $8K (income).
Period Ending: | Jan 31, 2022 | Oct 31, 2021 | Jul 31, 2021 | Apr 30, 2021 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -0.26 | -0.2 | -0.11 | -0.23 |
Net Income | 0.63 | 0.68 | 0.15 | -1.67 |
Period Ending: | Jan 31, 2022 | Oct 31, 2021 | Jul 31, 2021 | Apr 30, 2021 |
---|---|---|---|---|
Total Assets | 0.85 | 0.77 | 0.9 | 0.98 |
Total Liabilities | -0.33 | 0.39 | 1.2 | 2.06 |
Total Equity | 1.19 | 0.37 | -0.3 | -1.07 |
Period Ending: | Jan 31, 2022 | Oct 31, 2021 | Jul 31, 2021 | Apr 30, 2021 |
---|---|---|---|---|
Period Length: | 6 Months | 3 Months | 12 Months | 9 Months |
Cash From Operating Activities | -0.26 | -0.13 | -0.55 | -0.4 |
Cash From Investing Activities | -0.01 | -0.02 | -0.05 | |
Cash From Financing Activities | 0.22 | 0 | 1.42 | 1.36 |
Net Change in Cash | -0.05 | -0.14 | 0.82 | 0.96 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review